Please, enter the verification code that sent to your e-mail address
While most drugs work by binding to proteins, the newly discovered components first bind to rare targets, called microRNA precursors, involved in silencing gene transcription. It then activates the cell's own destruction system to destroy the cell. MicroRNA-21 is called oncogenic RNA because of its role in metastasis. The abundance of MicroRNA-21 predicts a lower survival rate for patients with triple-negative breast cancer.
Triple-negative breast cancer does not have properties that make it vulnerable to the sensitive anti-cancer drugs currently available. 10% to 15% of breast cancer patients get this diagnosis because their tumors have a negative sensitivity test to estrogen and progesterone, and HER2 protein production makes traditional chemotherapy first-line therapy.
Breast cancer affects one in eight women in their lifetime. Unfortunately, there are no sensitive medications for triple-negative breast cancer patients. And most of the time, these cancers become metastatic, spread. According to the researchers, this metastasis can result in death. Questioning whether they could develop a compound that could target genes that cause cancer metastasis and self-destruct of triple-negative breast cancer cells, researchers developed a tool called Inforna in 2014 to identify pesticide RNA structures and compounds selectively into microRNA-21, as it reveals the needle in a haystack. says he is connected.
The researchers combined the optimized compound with a second molecule that collects and activates an RNA-cutting enzyme that is part of our immune system. In this way, the compound achieved the destruction of the microRNA-21 target.
Chimeras with Ribonuclease Targeting
This sensitive target and destruction system is called "RIBOTAC", meaning "ribonuclease versus chimera". This tool represents a gene expression regulator that can completely delete disease-related sequences from RNA. Researchers have gone to great lengths to examine whether the compound identified by Inforna is selective - that is, whether it targets microRNA-21 without causing undesirable off-target effects. They studied important changes in the protein production of breast cancer cells and found positive results.
Researchers have gone to great lengths to examine whether the compound identified by Inforna is selective, i.e., whether it targets microRNA-21 without adverse off-target effects. They studied important changes in the protein production of breast cancer cells and found positive results.
In addition to triple-negative breast cancer, the research team also found that the compound greatly reduced the invasion of melanoma and lung cancer cell lines, which have abnormal microRNA-21 activity. The compound has no significant effect on healthy breast tissue.
Researchers say it is too early to say that this is an anti-traditional treatment. Traditional medicines work by binding to proteins because they are structurally more complex than RNA with only four bases. The researchers said they used chemical strategies to overcome this situation.